Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Follow-Up Questions
Who is the CEO of Protara Therapeutics Inc?
Mr. Jesse Shefferman is the President of Protara Therapeutics Inc, joining the firm since 2020.
What is the price performance of TARA stock?
The current price of TARA is $3.21, it has increased 0.03% in the last trading day.
What are the primary business themes or industries for Protara Therapeutics Inc?
Protara Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Protara Therapeutics Inc market cap?
Protara Therapeutics Inc's current market cap is $123.8M
Is Protara Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Protara Therapeutics Inc, including 3 strong buy, 8 buy, 1 hold, 0 sell, and 3 strong sell
